Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study With Galunisertib Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer With Peritoneal Metastases

NCT05700656 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT05700656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05700656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study With Galunisertib Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer With Peritoneal Metastases
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 28, 2023
Completion date
December 31, 2026
Enrollment
31 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic, peritoneal carcinomatosis